Business Context and Reporting Period
This Form 8-K filing by Teva Pharmaceutical Industries Ltd. covers the event date of September 14, 2026. The report details a significant change in the company's capital structure and trading mechanism on the New York Stock Exchange (NYSE).
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a current report regarding a corporate action rather than a periodic financial statement.
Material Changes
- Trading Instrument Change: On September 14, 2026, the Company began trading its ordinary shares on the NYSE, replacing its American Depositary Shares (ADSs).
- Exchange Ratio: The ADS program terminated with a 1:1 exchange ratio, where each ADS was exchanged for one ordinary share.
- Ticker Symbol: The ordinary shares continue to trade under the same ticker symbol, "TEVA," previously used for the ADSs.
- Dual Listing: The Company's ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol "TEVA."
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the operational change in share trading. Investors are directed to the Company's investor relations website (ir.tevapharm.com) for additional information.
Key Facts for Investor Verification
- Confirm the 1:1 exchange ratio of ADSs to ordinary shares was executed as of September 14, 2026.
- Verify that the NYSE ticker symbol "TEVA" now represents ordinary shares rather than ADSs.
- Check the Company's investor relations website for any supplementary details regarding the transition.